Laporan Laba Rugi (TTM)
Laporan Laba Rugi eFFECTOR Therapeutics, Inc. - Equity Warrant menunjukkan perubahan pendapatan dan pengeluaran selama periode waktu tertentu. Data Laporan Laba Rugi meliputi Penjualan dan Pendapatan, Laba Kotor, Penelitian dan Pengembangan (R&D), Beban Penjualan, Umum dan Administrasi (SG&A), Laba Operasi, Beban Pajak Penghasilan, Beban Bunga, Pendapatan Non-Operasi, Laba per Saham (EPS), dan Saham yang Beredar.
Semua angka adalah kelipatan 1,000,000 kecuali unit per saham.
|
2020 12-31 |
2021 03-31 |
2021 06-30 |
2021 09-30 |
2021 12-31 |
2022 03-31 |
2022 06-30 |
2022 09-30 |
2022 12-31 |
2023 03-31 |
2023 06-30 |
2023 09-30 |
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 42 | 16 | 1 | 1 | 1 | 1 | 3 | 3 | 4 | 4 | 2 | 1 |
| Change (%) | -62.69 | -91.65 | -11.24 | 23.17 | 0.00 | 92.24 | 16.01 | 11.41 | 0.00 | -56.60 | -56.23 | |
| % of Revenue | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 |
| Cost Of Sales | 22 | 21 | 20 | 18 | 20 | 19 | 21 | 23 | 23 | 27 | 25 | 23 |
| Change (%) | -5.30 | -3.65 | -8.82 | 9.87 | -6.79 | 15.31 | 7.51 | 1.11 | 15.00 | -7.60 | -5.16 | |
| % of Revenue | 51.98 | 131.93 | 1,523.01 | 1,564.43 | 1,395.52 | 1,300.70 | 780.17 | 723.02 | 656.15 | 754.57 | 1,606.49 | 3,480.74 |
| Gross Operating Profit | 20 | -5 | -19 | -17 | -19 | -17 | -19 | -20 | -20 | -23 | -23 | -23 |
| Change (%) | -124.81 | 271.96 | -8.66 | 8.96 | -7.32 | 8.90 | 6.26 | -0.54 | 17.70 | -0.12 | -1.76 | |
| % of Revenue | 48.02 | -31.93 | -1,423.01 | -1,464.43 | -1,295.52 | -1,200.70 | -680.17 | -623.02 | -556.15 | -654.57 | -1,506.49 | -3,380.74 |
| SG&A | 4 | 5 | 5 | 8 | 13 | 16 | 17 | 16 | 13 | 12 | 12 | 11 |
| Change (%) | 3.86 | 11.93 | 60.44 | 64.83 | 16.21 | 8.42 | -3.76 | -22.02 | -4.03 | 0.01 | -8.13 | |
| % of Revenue | 10.35 | 28.82 | 386.54 | 698.71 | 935.03 | 1,086.57 | 612.84 | 508.44 | 355.84 | 341.51 | 786.96 | 1,651.70 |
| R&D | ||||||||||||
| Change (%) | ||||||||||||
| % of Revenue | ||||||||||||
| OpEx | 26 | 25 | 25 | 26 | 33 | 34 | 38 | 39 | 36 | 39 | 37 | 35 |
| Change (%) | -3.78 | -0.85 | 5.20 | 26.84 | 2.43 | 12.17 | 2.55 | -8.44 | 8.31 | -5.23 | -6.13 | |
| % of Revenue | 62.34 | 160.76 | 1,909.56 | 2,263.14 | 2,330.56 | 2,387.27 | 1,393.02 | 1,231.45 | 1,011.99 | 1,096.09 | 2,393.45 | 5,132.44 |
| Operating Income | 16 | -10 | -24 | -25 | -32 | -33 | -36 | -36 | -32 | -35 | -35 | -34 |
| Change (%) | -160.19 | 148.60 | 6.11 | 27.01 | 2.54 | 8.67 | 1.51 | -10.20 | 9.22 | -0.07 | -3.95 | |
| % of Revenue | 37.66 | -60.76 | -1,809.56 | -2,163.14 | -2,230.56 | -2,287.27 | -1,293.02 | -1,131.45 | -911.99 | -996.09 | -2,293.45 | -5,032.44 |
| Interest Expense | -1 | -1 | -1 | -2 | -2 | -2 | -2 | -2 | -2 | -2 | -3 | -3 |
| Change (%) | -2.40 | 10.84 | 10.12 | 11.08 | 9.75 | 1.29 | 4.23 | 10.13 | 9.37 | 8.81 | 6.68 | |
| % of Revenue | -3.17 | -8.30 | -110.24 | -136.78 | -123.36 | -135.38 | -71.34 | -64.10 | -63.35 | -69.29 | -173.74 | -423.41 |
| Net Income | 0 | -7 | -40 | -23 | 16 | 25 | 24 | 6 | -23 | -36 | -37 | -36 |
| Change (%) | -4,408.43 | 454.22 | -41.60 | -168.24 | 61.09 | -5.37 | -76.56 | -501.58 | 57.72 | 4.05 | -3.38 | |
| % of Revenue | 0.40 | -45.64 | -3,030.43 | -1,993.97 | 1,104.76 | 1,779.65 | 876.03 | 176.98 | -637.91 | -1,006.14 | -2,412.26 | -5,324.59 |
Source: Capital IQ
